Utah Governor’s Office of Economic Development

Sera Prognostics will identify and commercialize peptide biomarkers that are predictive of preterm birth (13% of pregnancies), preeclampsia (5%) and other pregnancy complications. These biomarkers have emerged from the Joint Biomarker Center, a collaboration between BYU and the University of Utah with blood samples provided by the U of U and serum proteomics performed at BYU. So far, Sera has identified 5 biomarkers for PTB and 2 for PE. Both conditions can be treated, with outcomes significantly improved by early detection.